ATyr Pharma, Inc. Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, Atyr2810, on Tumor Associated Macrophages At the Society for Immunotherapy of Cancer Annual Meeting
November 09, 2021 at 08:05 am EST
Share
aTyr Pharma, Inc. announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, which is being held November 10 ? 14, 2021 in Washington, DC, and virtually. The full text of the corresponding abstract is available on the SITC website. The poster will be available for browsing on the SITC website starting November 12 at 7:00 a.m. ET through November 14 at 5:00 p.m. ET. The poster presents preclinical findings for ATYR2810, providing key insights into its mechanism of action that will help support the clinical development of ATYR2810, including a Phase 1 study in cancer next year. ATYR2810, an anti-Neuropilin-2 (NRP2) monoclonal antibody that blocks NRP2?s VEGF-induced signaling axis, was developed from aTyr?s research platform focused on targeting human disease pathways associated with extracellular tRNA synthetases. This work details the effects of ATYR2810 on tumor associated macrophages (TAMs) differentiated from human triple-negative breast cancer tumor cells. Treatment with ATYR2810 was shown to decrease the suppressive capabilities of TAMs against T cells compared to untreated TAMs. Furthermore, TAMs treated with ATYR2810 showed a decrease in ZEB1 gene expression, which is a master transcription factor regulating epithelial-mesenchymal transition (EMT), a process that is of great importance in regulating tumor growth, progression and metastatic cascade as well as being implicated in tumor evasion of the immune system. These results suggest that ATYR2810 may be able to treat cancer by targeting tumor immune avoidance mechanisms as well as regulating EMT.
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
ATyr Pharma, Inc. Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, Atyr2810, on Tumor Associated Macrophages At the Society for Immunotherapy of Cancer Annual Meeting